Metis TechBio Co., Ltd. (Ticker: 7666 HK) is a Chinese AI-driven drug formulation and nanomaterial innovation company focused on applying artificial intelligence, molecular simulation, quantum chemistry, and high-throughput screening to therapeutic delivery and formulation development. The company’s platforms include NanoForge, AiTEM, AiLNP and AiRNA, supporting applications in human therapeutics, longevity and animal health. Its most advanced drug candidate, MTS-004, has completed Phase III clinical trial development.

Metis TechBio plans to list H shares on the Hong Kong Stock Exchange Main Board on May 13, 2026. According to published terms, the company is offering 201.23 million primary shares at HKD 10.50 per share, raising approximately HKD 2.11 billion, or about $270 million. The market capitalization at offer is approximately $1.4 billion. The offering includes a 15% greenshoe option.

According to the prospectus, proceeds will be used for R&D and product capacity, brand promotion and business development, working capital, strategic acquisitions and other purposes. The IPO managers include CLSA, CMB International, Deutsche Bank, Futu Securities and Jefferies.